ATHX Key Stats
|Revenue (Quarterly YoY Growth)||-38.82%|
|EPS Diluted (TTM)||-0.4612|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-24.18M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-904.0%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- ATHERSYS, INC / NEW Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 3
- Athersys to Raise Funds - Analyst Blog Zacks Dec 2
- Athersys to Raise Funds Dec 2
- ATHERSYS, INC / NEW Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 29
- Athersys Prices Registered Direct Offering of Common Stock and Warrants noodls Nov 27
- Athersys (ATHX) Catches Eye: Stock Jumps 5.5% Nov 26
- Athersys (ATHX) Catches Eye: Stock Jumps 5.5% - Tale of the Tape Zacks Nov 26
- Athersys to Present at 25th Annual Piper Jaffray Healthcare Conference noodls Nov 25
- CORRECTION: Athersys to Present at 25th Annual Piper Jaffray Healthcare Conference noodls Nov 25
- 4 Biotech Stocks Making Big Moves Wall St. Cheat Sheet Nov 23
ATHX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Athersys is up 85.71% over the last year vs S&P 500 Total Return up 30.68%, Actelion up 64.18%, and Cleveland BioLabs down 18.46%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for ATHX
Pro Strategies Featuring ATHX
Did Athersys make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Athersys Inc. is a biopharmaceutical company that is focused in the field of regenerative medicine. It is engaged in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life.